
 <b>CERTIFICATE OF MAILING</b>		
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date.		
Typed or Printed Name	Cindy Kim Hoang	
Signature		
Date	June 28, 2002	
<b>INFORMATION DISCLOSURE STATEMENT</b>  Address to: Commissioner for Patents Washington, D.C. 20231	Attorney Docket	UCSF-265
	First Named Inventor	WABL, MATTHIAS
	Application Number	10/087,144
	Confirmation No.	4410
	Filing Date	March 1, 2002
	Group Art Unit	1743
	Examiner Name	To Be Assigned
	Title: "METHODS FOR IDENTIFYING AGENTS THAT MODULATE MAST CELL DEGRANULATION"	

RECEIVED  
JUL 10 2002  
TIC 1700

Sir:


This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. § 102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. UCSF-265 may be charged thereon.

Respectfully submitted,  
 BOZICEVIC, FIELD & FRANCIS LLP

Date: June 28, 2002

By:   
 Paula A. Borden  
 Registration No. 42,344

BOZICEVIC, FIELD & FRANCIS LLP  
 200 Middlefield Road, Suite 200  
 Menlo Park, CA 94025  
 Telephone: (650) 327-3400  
 Facsimile: (650) 327-3231

Please type a plus sign (+) inside this box →



JUL 05 2002

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/087,144
		Filing Date	March 1, 2002
		First Named Inventor	Wabl, et al.
		Group Art Unit	1743
		Examiner Name	Unassigned
Sheet 1 of 2	Attorney Docket Number	UCSF-265	

U.S. PATENT DOCUMENTS						
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Documents			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		BORGGREFE, et al. "A B-cell-specific DNA recombination complex", <i>Journ. Biol. Chem.</i> , (1998) Vol. 273: 17025-17035.	
		BORGGREFE, et al. "Cellular, intracellular, and developmental expression patterns of murine SWAP-70", <i>Europ. J. Immunol.</i> , (1999) Vol. 29: 1812-1822.	
		BORGGREFE, et al. "Impaired IgE response in SWAP-70-deficient mice", <i>Europ. J. Immunol.</i> , (2001) Vol. 31: 2467-2475.	
		DAËRON. "Fc receptor biology", <i>Ann. Rev. Immunol.</i> , (1997) Vol. 15: 203-234.	
		DEMO, et al. "Quantitative measurement of mast cell degranulation using a novel flow cytometric annexin-V binding assay". <i>Cytometry</i> , (1999) Vol. 36: 340-348.	
		GALLI, et al. "Mast cell and basophil development", <i>Curr. Opin. Haematol.</i> , (1994) Vol. 1: 33-39.	
		GALLI, et al. "Mast cells and basophils", <i>Curr. Opin. Haematol.</i> , (2000) Vol. 7: 32-39.	
		GOMPERT, et al. "Regulated exocytotic secretion from permeabilized cells", <i>Meth. Enzym.</i> , (1992) Vol. 219: 178-189.	
		GRAWUNDER, et al. "Expression of DNA-dependent protein kinase holoenzyme upon induction of lymphocyte differentiation and V(D)J recombination", <i>Eur. J. Biochem.</i> , (1996) Vol. 241: 931-940.	
		IEMURA, et al. "The c-kit ligand, stem cell factor, promotes mast cell survival by suppressing apoptosis", <i>Am. J. Pathol.</i> , (1994) Vol. 144: 321-328.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/087,144
				Filing Date	March 1, 2002
				First Named Inventor	Wabl, et al.
				Group Art Unit	1743
				Examiner Name	Unassigned
Sheet	2	of	2	Attorney Docket Number	UCSF-265

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		KITAMURA, et al. Presence of mast cell precursors in peripheral blood of mice demonstrated by parabiosis", <i>Blood</i> , (1979) Vol. 53: 1085-1088.	—
		LI, et al. "Mast-cell growth and differentiation", <i>Allergy</i> , (1999) Vol. 54: 306-312.	—
		LOO, et al. "Measurement of cell death", <i>Meth. Cell Biol.</i> , (1998) Vol. 57: 251-264.	—
		MASAT, et al. "Association of SWAP-70 with the B cell antigen receptor complex", <i>Proc. Natl. Acad. Sci. US A</i> , (2000) Vol. 97: 2180-2184.	—
		MITSUI, et al. "Development of human mast cells from umbilical cord blood cells by recombinant human and murine c-kit ligand", <i>Proc. Natl. Acad. Sci. USA</i> , (1993) Vol. 90: 735-739.	—
		RODEWALD, et al. "Identification of a committed precursor for the mast cell lineage", <i>Science</i> , (1996) Vol. 271: 818-822.	—
		ROTTEM, et al. "Kinetics of the appearance of Fc <sub>ε</sub> RI-bearing cells in interleukin-3-dependent mouse bone marrow cultures: Correlation with histamine content and mast cell maturation", <i>Blood</i> , (1992) Vol. 9: 972-980.	—
		SONODA, et al. "Concentration of mast-cell progenitors in bone marrow, spleen, and blood of mice determined by limited dilution analysis", <i>J. Cell. Physiol.</i> , (1982) Vol. 112: 136-140.	—
		TURNER, et al. "Signaling through the high-affinity IgE receptor Fc <sub>ε</sub> RI", <i>Nature</i> , (1999) Vol. 402 supp.: B24-B29.	—
		VALENT, et al. "Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kit-ligand in long-term culture", <i>Blood</i> , (1992) Vol. 80: 2237-2245.	—
		VAN ENGELAND, et al. "Annexin V-affinity assay: A review on an apoptosis detection system based on phosphatidylserine exposure", <i>Cytometry</i> , (1998) Vol. 31: 1-9.	—
		YEE, et al. "Role of <i>kit</i> -ligand in proliferation and suppression of apoptosis in mast cells: Basis for radiosensitivity of <i>White Spotting</i> and <i>Steel</i> mutant mice", <i>J. Exp. Med.</i> , (1994) Vol. 179: 1777-1787.	—
		YONG. "The mast cell: Origin, morphology, distribution, and function", <i>Exp. Toxic Pathol.</i> , (1997) Vol. 49: 409-424.	—

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.